• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Eisai Ltd ADR (OP: ESALY )

    N/A UNCHANGED
    Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eisai Ltd ADR

    < Previous 1 2 3 4 5 6 7 Next >
    2 Signals to Watch Before Buying SAVA Stock
    SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play. 
    Via InvestorPlace
    These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
    Via Benzinga
    Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results
    Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring. 
    Via InvestorPlace
    Why Is Acumen (ABOS) Stock Up 95% Today?
    Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company. 
    Via InvestorPlace
    This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
    Via Benzinga
    Why Is Biogen (BIIB) Stock Up 40% Today?
    Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors. 
    Via InvestorPlace
    Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
    Via Benzinga
    Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
    Via Benzinga
    Why Acumen Pharmaceuticals Stock Is Soaring Today
    Acumen Pharmaceuticals Inc (NASDAQ: ABOS) shares are trading higher Wednesday after Biogen Inc (NASDAQ: BIIB) and Eisai Co (Pink: 
    Via Benzinga
    Why Is Cassava Sciences (SAVA) Stock Heating Up Today?
    SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target. 
    Via InvestorPlace
    Is iPhone Demand Really Slowing Down?, Lyft Freezes Hiring, Biogen's New Drug Slows Alzheimer's Progression: Top Financial Media Stories Wednesday, Sept. 28
    Bloomberg 
    Via Benzinga
    What In The World Is Going On With Biogen (BIIB) Shares?
    Biogen Inc (NASDAQ: BIIB) shares are trading higher by 42.62% to $282.08 during Wednesday's pre-market session after the company and Eisai Co. 
    Via Benzinga
    Why Cassava Sciences Shares Are Soaring Higher
    Cassava Sciences Inc (NASDAQ: SAVA) shares are trading higher by 7.15 to $49.48 during Wednesday's pre-market session after Biogen Inc (NASDAQ: BIIB) and Eisai Co. 
    Via Benzinga
    Why Biogen Stock Is Up 40% Today
    Biogen, Inc. (NASDAQ: BIIB) shares are soaring over 43% to their highest level in about a year in premarket trading Wednesday. 
    Via Benzinga
    2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
    Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd. 
    Via Benzinga
    US Stock Futures Down Ahead Of Fed Speakers, Economic Data
    Pre-open movers U.S. stock futures traded lower in early pre-market trade on Wednesday after closing mostly lower on Tuesday. The S&P 500 index dropped deeper into a bear market after hitting a fresh... 
    Via Benzinga
    Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
    Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. 
    Via Benzinga
    Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
    Via Benzinga
    Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
    Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).  
    Via Benzinga
    Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
    Eisai finished submitting its application for lecanemab, another anti-amyloid drug. 
    Via Investor's Business Daily
    The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
    Via Benzinga
    The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
    In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have  
    Via Benzinga
    FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
    The  
    Via Benzinga
    News-Filled Day
    The price of oil fell to below $100/oz on the prospect of lower demand from the PRC. 
    Via Talk Markets
    The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Hopes For A Peace Accord
    The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
    Via Talk Markets
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.